Chardan Capital restated their neutral rating on shares of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) in a research note released on Sunday morning.

Several other analysts have also recently weighed in on ACHN. Zacks Investment Research cut shares of Achillion Pharmaceuticals from a hold rating to a sell rating in a research note on Friday, August 11th. Robert W. Baird cut shares of Achillion Pharmaceuticals from an outperform rating to a neutral rating and set a $5.00 price objective for the company. in a research note on Thursday, August 10th. Maxim Group set a $7.00 price objective on shares of Achillion Pharmaceuticals and gave the stock a buy rating in a research note on Wednesday, August 9th. BidaskClub upgraded shares of Achillion Pharmaceuticals from a strong sell rating to a sell rating in a research note on Wednesday, August 16th. Finally, Ladenburg Thalmann Financial Services dropped their price objective on shares of Achillion Pharmaceuticals from $9.00 to $6.50 and set a buy rating for the company in a research note on Tuesday, September 12th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and four have assigned a buy rating to the company. Achillion Pharmaceuticals currently has an average rating of Hold and a consensus price target of $6.50.

Achillion Pharmaceuticals (NASDAQ ACHN) opened at 3.86 on Friday. Achillion Pharmaceuticals has a 52-week low of $3.15 and a 52-week high of $9.19. The firm’s market cap is $527.90 million. The company has a 50-day moving average of $4.48 and a 200 day moving average of $4.20.

Achillion Pharmaceuticals (NASDAQ:ACHN) last issued its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, hitting the consensus estimate of ($0.16). During the same quarter last year, the firm posted ($0.14) earnings per share. On average, equities research analysts anticipate that Achillion Pharmaceuticals will post ($0.66) EPS for the current year.

ILLEGAL ACTIVITY WARNING: “Achillion Pharmaceuticals, Inc. (ACHN) Given “Neutral” Rating at Chardan Capital” was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another domain, it was copied illegally and republished in violation of international copyright & trademark laws. The correct version of this article can be read at https://www.watchlistnews.com/achillion-pharmaceuticals-inc-achn-given-neutral-rating-at-chardan-capital/1575198.html.

Several large investors have recently modified their holdings of ACHN. Bank of Montreal Can raised its position in shares of Achillion Pharmaceuticals by 12,296.5% in the 1st quarter. Bank of Montreal Can now owns 53,305 shares of the biopharmaceutical company’s stock valued at $224,000 after buying an additional 52,875 shares in the last quarter. Wells Fargo & Company MN raised its position in shares of Achillion Pharmaceuticals by 11.9% in the 1st quarter. Wells Fargo & Company MN now owns 215,820 shares of the biopharmaceutical company’s stock valued at $908,000 after buying an additional 22,931 shares in the last quarter. Canada Pension Plan Investment Board raised its position in shares of Achillion Pharmaceuticals by 4.7% in the 1st quarter. Canada Pension Plan Investment Board now owns 35,800 shares of the biopharmaceutical company’s stock valued at $151,000 after buying an additional 1,600 shares in the last quarter. UBS Asset Management Americas Inc. raised its position in shares of Achillion Pharmaceuticals by 83.8% in the 1st quarter. UBS Asset Management Americas Inc. now owns 53,669 shares of the biopharmaceutical company’s stock valued at $226,000 after buying an additional 24,471 shares in the last quarter. Finally, Parametric Portfolio Associates LLC raised its position in shares of Achillion Pharmaceuticals by 304.7% in the 1st quarter. Parametric Portfolio Associates LLC now owns 103,263 shares of the biopharmaceutical company’s stock valued at $435,000 after buying an additional 77,748 shares in the last quarter. Institutional investors own 74.11% of the company’s stock.

About Achillion Pharmaceuticals

Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.

Analyst Recommendations for Achillion Pharmaceuticals (NASDAQ:ACHN)

Receive News & Ratings for Achillion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.